Prothena’s amyloid mAb may have right profile for at home treatment

With higher binding affinity than Leqembi and greater potency than donanemab, Prothena believes its latest preclinical findings point to best-in-class potential for anti-amyloid mAb PRX012. The company is hoping the therapy, which was designed for subcutaneous delivery, will increase access to treatment for Alzheimer’s patients.

“The goal with PRX012 was to think about the patient experience from an access perspective,” Gene Kinney, president and CEO of Prothena Corp. plc (NASDAQ:PRTA), told BioCentury. “We rationally designed this for a subcutaneous single syringe presentation. We weren’t trying to reformulate to subcutaneous.” ...